tiprankstipranks
Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c
The Fly

Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c

Backs FY24 revenue view $2.7B-$2.8B, consensus $2.76B. Backs FY24 adjusted EBITDA $610M-$630M.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App